CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: tanespimycin
Accession: CHEBI:64153
browse the term
Definition: A 19-membered macrocyle that is geldanamycin in which the methoxy substituent attached to the benzoquinone moiety has been replaced by an allylamino group. It is a potent inhibitor of heat shock protein 90 (Hsp90). A less toxic analogue than geldanamycin, it induces apoptosis and displays antitumour effects.
Synonyms: exact_synonym: (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-en-1-ylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate
related_synonym: 17-(Allylamino)-17-demethoxygeldanamycin; 17-(Allylamino)geldanamycin; 17-AAG; 17-Demethoxy-17-allylamino geldanamycin; 17-N-allylamino-17-demethoxygeldanamycin; 17-allylaminogeldanamycin; 17-demethoxy-17-(2-propenylamino)geldanamycin; 17AAG; Formula=C31H43N3O8; InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1; InChIKey=AYUNIORJHRXIBJ-TXHRRWQRSA-N; NSC-330507; SMILES=C=1C(C(=C2C(C1NC(=O)C(C)=CC=C[C@@H]([C@@H](OC(N)=O)C(C)=C[C@@H]([C@H]([C@H](C[C@@H](C2)C)OC)O)C)OC)=O)NCC=C)=O; tanespimycina; tanespimycine; tanespimycinum
alt_id: MESH:C112765
xref: CAS:75747-14-7; KEGG:D06650
xref_mesh: MESH:C112765
xref: PMID:20646760; PMID:20652703; PMID:20683637; PMID:21219297; PMID:21283735; PMID:21454186; PMID:21534941; PMID:21558407; PMID:21594721; PMID:21670086; PMID:21791475; PMID:21856392; PMID:22047770; PMID:22209975; PMID:22377218; PMID:22621282; PMID:23564374; PMID:24317439; PMID:25096912; PMID:25633180; PMID:25952464; PMID:26277605; PMID:26408708; PMID:26872308; PMID:26913406; PMID:26922527; PMID:27045471; Reaxys:7402240; Wikipedia:17-N-Allylamino-17-demethoxygeldanamycin
G
Abhd11
abhydrolase domain containing 11
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of ABHD11 protein
CTD
PMID:31370342
NCBI chr12:21,682,206...21,685,331
Ensembl chr12:21,682,202...21,685,398
G
Actr1a
actin related protein 1A
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of ACTR1A protein
CTD
PMID:31370342
NCBI chr 1:245,237,821...245,256,618
Ensembl chr 1:245,237,826...245,256,495
G
Adamts1
ADAM metallopeptidase with thrombospondin type 1 motif, 1
increases expression
ISO
tanespimycin results in increased expression of ADAMTS1 mRNA
CTD
PMID:19514085
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
G
Agr2
anterior gradient 2, protein disulphide isomerase family member
multiple interactions increases expression
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of AGR2 protein tanespimycin analog results in increased expression of AGR2 protein; tanespimycin results in increased expression of AGR2 protein
CTD
PMID:31370342
NCBI chr 6:52,708,602...52,729,378
Ensembl chr 6:52,708,602...52,729,371
G
Ahr
aryl hydrocarbon receptor
multiple interactions decreases expression
ISO
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tanespimycin results in decreased expression of AHR protein]
CTD
PMID:37217010
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
G
Ak9
adenylate kinase 9
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of AK9 protein
CTD
PMID:31370342
NCBI chr20:44,724,494...44,941,135
Ensembl chr20:44,724,496...44,941,136
G
Akt1
AKT serine/threonine kinase 1
multiple interactions affects expression decreases expression
ISO EXP
Arsenic Trioxide promotes the reaction [tanespimycin results in decreased expression of AKT1 protein]; tanespimycin affects the reaction [Cannabidiol affects the expression of AKT1 protein]; tanespimycin promotes the reaction [Arsenic Trioxide results in decreased expression of AKT1 protein]; tanespimycin results in decreased expression of and results in decreased phosphorylation of AKT1 protein tanespimycin affects the expression of AKT1 protein
CTD
PMID:16923571 PMID:17157164 PMID:18566239 PMID:22810956 PMID:26504004
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
G
Alb
albumin
affects binding multiple interactions
ISO
ALB protein binds to tanespimycin ALB protein inhibits the reaction [Copper results in increased oxidation of tanespimycin analog]
CTD
PMID:18393300
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
G
Aldh1a1
aldehyde dehydrogenase 1 family, member A1
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of ALDH1A1 protein
CTD
PMID:31370342
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
G
Alk
ALK receptor tyrosine kinase
decreases activity decreases expression
ISO
tanespimycin results in decreased activity of ALK protein mutant form tanespimycin results in decreased expression of ALK protein; tanespimycin results in decreased expression of ALK protein modified form
CTD
PMID:21030459 PMID:21502504
NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034
G
Anxa1
annexin A1
increases expression
ISO
tanespimycin results in increased expression of ANXA1 protein
CTD
PMID:31370342
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
G
Apaf1
apoptotic peptidase activating factor 1
multiple interactions increases expression
ISO
Scorpion Venoms results in increased susceptibility to [tanespimycin results in increased expression of APAF1 protein]
CTD
PMID:19913524
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
G
Ar
androgen receptor
decreases expression
ISO
tanespimycin results in decreased expression of AR protein
CTD
PMID:17010675
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Atp5f1a
ATP synthase F1 subunit alpha
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of ATP5F1A protein
CTD
PMID:31370342
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
G
Atp5f1b
ATP synthase F1 subunit beta
decreases expression
ISO
tanespimycin analog results in decreased expression of ATP5F1B protein
CTD
PMID:31370342
NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
G
Bcl2
BCL2, apoptosis regulator
decreases expression
ISO
tanespimycin results in decreased expression of BCL2 protein
CTD
PMID:16923571 PMID:28673683
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
G
Bcl2l1
Bcl2-like 1
decreases expression
ISO
tanespimycin results in decreased expression of BCL2L1 protein
CTD
PMID:16923571
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
G
Bcl2l11
Bcl2-like 11
increases expression
ISO
tanespimycin results in increased expression of BCL2L11 protein
CTD
PMID:24784839
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
G
Braf
B-Raf proto-oncogene, serine/threonine kinase
increases expression decreases expression
ISO EXP
tanespimycin analog results in increased expression of BRAF protein tanespimycin results in decreased expression of BRAF protein
CTD
PMID:22810956 PMID:31370342
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
G
Casp3
caspase 3
multiple interactions increases cleavage increases activity
ISO EXP
[tanespimycin co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; Scorpion Venoms results in increased susceptibility to [tanespimycin results in increased activity of CASP3 protein]; tanespimycin results in increased cleavage of and results in increased activity of CASP3 protein tanespimycin results in increased cleavage of CASP3 protein SH-6 compound promotes the reaction [tanespimycin promotes the reaction [Dopamine results in increased activity of CASP3 protein]]; tanespimycin promotes the reaction [Dopamine results in increased activity of CASP3 protein]
CTD
PMID:15993848 PMID:17157164 PMID:18194434 PMID:19913524 PMID:22810956 PMID:24189122 More...
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
G
Casp8
caspase 8
increases cleavage multiple interactions
ISO
tanespimycin results in increased cleavage of CASP8 protein [tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP8 protein
CTD
PMID:17121904
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
G
Casp9
caspase 9
multiple interactions increases cleavage
ISO
[tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP9 protein tanespimycin results in increased cleavage of CASP9 protein
CTD
PMID:17121904
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
G
Ccnd1
cyclin D1
decreases expression multiple interactions
ISO
tanespimycin results in decreased expression of CCND1 protein [Sirolimus co-treated with tanespimycin] results in decreased expression of CCND1 protein
CTD
PMID:17121904 PMID:17157164
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
G
Cct8
chaperonin containing TCP1 subunit 8
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of CCT8 protein
CTD
PMID:31370342
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
G
Cdc25c
cell division cycle 25C
multiple interactions decreases expression
ISO EXP
[tanespimycin co-treated with NQO1 protein] results in decreased expression of CDC25C protein tanespimycin results in decreased expression of CDC25C protein
CTD
PMID:21156818 PMID:22810956
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
G
Cdk1
cyclin-dependent kinase 1
multiple interactions affects expression decreases expression
ISO
[tanespimycin co-treated with NQO1 protein] results in decreased expression of CDK1 protein; tanespimycin affects the reaction [Cannabidiol affects the expression of CDK1 protein] tanespimycin affects the expression of CDK1 protein tanespimycin results in decreased expression of CDK1 protein
CTD
PMID:21156818 PMID:24784839 PMID:26504004
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
G
Cdk4
cyclin-dependent kinase 4
decreases expression
ISO
tanespimycin results in decreased expression of CDK4 protein
CTD
PMID:17157164 PMID:28673683 PMID:34291863
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
G
Cdk8
cyclin-dependent kinase 8
decreases expression
ISO
tanespimycin results in decreased expression of CDK8 protein
CTD
PMID:17157164
NCBI chr12:8,737,198...8,805,026
Ensembl chr12:8,737,262...8,804,177
G
Cebpb
CCAAT/enhancer binding protein beta
decreases expression
ISO
tanespimycin results in decreased expression of CEBPB protein
CTD
PMID:33609515
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
G
Ces1d
carboxylesterase 1D
increases expression
ISO
tanespimycin analog results in increased expression of CES1 protein
CTD
PMID:31370342
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
G
Chp2
calcineurin-like EF hand protein 2
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of CHP2 protein
CTD
PMID:31370342
NCBI chr 1:176,757,945...176,772,443
Ensembl chr 1:176,757,876...176,772,139
G
Commd1
copper metabolism domain containing 1
multiple interactions
ISO
tanespimycin promotes the reaction [COMMD1 protein results in increased degradation of HIF1A protein]
CTD
PMID:19802386
NCBI chr14:96,880,463...96,984,494
Ensembl chr14:96,880,463...96,984,501
G
Csde1
cold shock domain containing E1
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of CSDE1 protein
CTD
PMID:31370342
NCBI chr 2:190,546,015...190,582,787
Ensembl chr 2:190,554,980...190,582,784
G
Cttn
cortactin
multiple interactions increases expression
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of CTTN protein tanespimycin analog results in increased expression of CTTN protein
CTD
PMID:31370342
NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164
G
Cyp3a9
cytochrome P450, family 3, subfamily a, polypeptide 9
affects metabolic processing
ISO
CYP3A5 protein affects the metabolism of tanespimycin
CTD
PMID:15718306
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
G
Dars1
aspartyl-tRNA synthetase 1
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of DARS1 protein
CTD
PMID:31370342
NCBI chr13:39,857,936...39,913,055
Ensembl chr13:39,857,936...39,913,116
G
Dhrs2
dehydrogenase/reductase 2
increases expression
ISO
tanespimycin results in increased expression of DHRS2 protein
CTD
PMID:31370342
NCBI chr15:28,688,881...28,703,646
Ensembl chr15:28,688,940...28,703,644
G
Ebf2
EBF transcription factor 2
increases expression
ISO
tanespimycin analog results in increased expression of EBF2 protein
CTD
PMID:31370342
NCBI chr15:41,435,509...41,634,403
Ensembl chr15:41,435,509...41,634,403
G
Echdc3
enoyl CoA hydratase domain containing 3
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of ECHDC3 protein
CTD
PMID:31370342
NCBI chr17:72,070,697...72,093,519
Ensembl chr17:72,070,668...72,093,516
G
Eef1g
eukaryotic translation elongation factor 1 gamma
multiple interactions decreases expression
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of EEF1G protein tanespimycin analog results in decreased expression of EEF1G protein
CTD
PMID:31370342
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
G
Eef2
eukaryotic translation elongation factor 2
increases expression multiple interactions
ISO
tanespimycin analog results in increased expression of EEF2 protein; tanespimycin results in increased expression of EEF2 protein [tanespimycin co-treated with VER 155008] results in increased expression of EEF2 protein
CTD
PMID:31370342
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
G
Egfr
epidermal growth factor receptor
decreases expression multiple interactions
ISO
tanespimycin analog results in decreased expression of EGFR protein; tanespimycin results in decreased expression of EGFR protein tanespimycin results in increased degradation of and results in decreased expression of EGFR protein
CTD
PMID:16061882 PMID:17010675 PMID:22810956 PMID:31370342
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
G
Eif3i
eukaryotic translation initiation factor 3, subunit I
decreases expression multiple interactions
ISO
tanespimycin results in decreased expression of EIF3I protein [tanespimycin co-treated with VER 155008] results in decreased expression of EIF3I protein
CTD
PMID:31370342
NCBI chr 5:141,935,135...141,942,589
Ensembl chr 5:141,935,044...141,942,676
G
Eif4b
eukaryotic translation initiation factor 4B
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of EIF4B protein
CTD
PMID:31370342
NCBI chr 7:133,206,637...133,228,436
G
Eif4h
eukaryotic translation initiation factor 4H
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of EIF4H protein
CTD
PMID:31370342
NCBI chr12:22,083,155...22,099,876
Ensembl chr12:22,082,835...22,099,876
G
Eml5
EMAP like 5
multiple interactions increases expression
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of EML5 protein tanespimycin analog results in increased expression of EML5 protein
CTD
PMID:31370342
NCBI chr 6:118,046,655...118,175,831
Ensembl chr 6:118,046,655...118,175,831
G
Eno1
enolase 1
increases expression
ISO
tanespimycin analog results in increased expression of ENO1 protein
CTD
PMID:31370342
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336 Ensembl chr 3:160,719,951...160,731,336
G
Erbb2
erb-b2 receptor tyrosine kinase 2
multiple interactions decreases expression
ISO
tanespimycin results in increased degradation of and results in decreased expression of ERBB2 protein tanespimycin results in decreased expression of ERBB2 protein
CTD
PMID:16061882 PMID:24784839 PMID:34291863
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
G
Eri1
exoribonuclease 1
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of ERI1 protein
CTD
PMID:31370342
NCBI chr16:56,724,101...56,744,228
Ensembl chr16:56,724,115...56,744,226
G
Erp29
endoplasmic reticulum protein 29
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of ERP29 protein
CTD
PMID:31370342
NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376
G
Farsb
phenylalanyl-tRNA synthetase subunit beta
multiple interactions increases expression
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of FARSB protein tanespimycin analog results in increased expression of FARSB protein; tanespimycin results in increased expression of FARSB protein
CTD
PMID:31370342
NCBI chr 9:79,887,852...79,947,082
Ensembl chr 9:79,887,842...79,947,045
G
Fgf1
fibroblast growth factor 1
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of FGF1 protein
CTD
PMID:31370342
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
G
Fgfr3
fibroblast growth factor receptor 3
multiple interactions
ISO
tanespimycin results in increased degradation of and results in decreased expression of FGFR3 protein
CTD
PMID:16061882
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
G
Flt3
Fms related receptor tyrosine kinase 3
decreases expression
ISO
tanespimycin results in decreased expression of FLT3 protein
CTD
PMID:17010675
NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474
G
Fubp1
far upstream element binding protein 1
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of FUBP1 protein
CTD
PMID:31370342
NCBI chr 2:241,159,481...241,186,591
Ensembl chr 2:241,159,512...241,186,602
G
Gcfc2
GC-rich sequence DNA-binding factor 2
increases expression
ISO
tanespimycin analog results in increased expression of GCFC2 protein
CTD
PMID:31370342
NCBI chr 4:114,481,613...114,519,268
Ensembl chr 4:114,481,607...114,519,962
G
Gls
glutaminase
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of GLS protein
CTD
PMID:31370342
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
G
Gsk3b
glycogen synthase kinase 3 beta
decreases expression
ISO
tanespimycin results in decreased expression of GSK3B protein modified form
CTD
PMID:20090934
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
G
Gtf2a2
general transcription factor 2A subunit 2
increases expression
ISO
tanespimycin analog results in increased expression of GTF2A2 protein
CTD
PMID:31370342
NCBI chr 8:70,662,447...70,675,576
Ensembl chr 8:70,662,428...70,675,569
G
Gtf2ird1
GTF2I repeat domain containing 1
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of GTF2IRD1 protein
CTD
PMID:31370342
NCBI chr12:22,254,113...22,361,052
Ensembl chr12:22,254,221...22,361,040
G
Hif1a
hypoxia inducible factor 1 subunit alpha
multiple interactions
ISO
tanespimycin promotes the reaction [COMMD1 protein results in increased degradation of HIF1A protein]
CTD
PMID:19802386
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
G
Hint1
histidine triad nucleotide binding protein 1
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of HINT1 protein
CTD
PMID:31370342
NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568
G
Hsd17b10
hydroxysteroid (17-beta) dehydrogenase 10
decreases expression multiple interactions
ISO
tanespimycin analog results in decreased expression of HSD17B10 protein; tanespimycin results in decreased expression of HSD17B10 protein [tanespimycin co-treated with VER 155008] results in decreased expression of HSD17B10 protein
CTD
PMID:31370342
NCBI chr X:21,089,142...21,091,603
Ensembl chr X:21,089,122...21,109,488
G
Hsf1
heat shock transcription factor 1
affects localization increases activity multiple interactions
ISO
tanespimycin affects the localization of HSF1 protein tanespimycin results in increased activity of HSF1 protein [tanespimycin affects the localization of HSF1 protein] which results in increased expression of HSPA1A protein
CTD
PMID:20090934 PMID:34170685
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
G
Hsp90aa1
heat shock protein 90 alpha family class A member 1
multiple interactions affects binding decreases expression
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of HSP90AA1 protein; N-(5-methylisoxazol-3-yl)-2-(4-(thiophen-2-yl)-6-(trifluoromethyl)pyrimidin-2-ylthio)acetamide inhibits the reaction [tanespimycin binds to HSP90AA1 protein] tanespimycin results in decreased expression of HSP90AA1 protein
CTD
PMID:18830594 PMID:22895790 PMID:31370342
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
G
Hsp90ab1
heat shock protein 90 alpha family class B member 1
affects binding
ISO
tanespimycin binds to HSP90AB1 protein
CTD
PMID:22895790
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
G
Hspa1a
heat shock protein family A (Hsp70) member 1A
multiple interactions increases expression
ISO
[tanespimycin affects the localization of HSF1 protein] which results in increased expression of HSPA1A protein tanespimycin analog results in increased expression of HSPA1A protein
CTD
PMID:20090934 PMID:31370342
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
G
Hspa1b
heat shock protein family A (Hsp70) member 1B
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of HSPA1B protein
CTD
PMID:31370342
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
G
Hspa4
heat shock protein family A (Hsp70) member 4
increases expression multiple interactions
ISO
tanespimycin results in increased expression of HSPA4 protein [tanespimycin results in increased expression of HSPA4 protein] which results in decreased susceptibility to Doxorubicin
CTD
PMID:16311509
NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001
G
Hspa5
heat shock protein family A (Hsp70) member 5
increases expression
ISO
tanespimycin results in increased expression of HSPA5 protein
CTD
PMID:16357177
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
G
Hspa6l-ps1
heat shock protein family A (Hsp70) member 6 like, pseudogene 1
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of HSPA6 protein
CTD
PMID:31370342
NCBI chr13:83,273,176...83,274,317
G
Hspd1
heat shock protein family D (Hsp60) member 1
decreases expression multiple interactions
ISO
tanespimycin results in decreased expression of HSPD1 protein [tanespimycin co-treated with VER 155008] results in decreased expression of HSPD1 protein
CTD
PMID:23144451 PMID:31370342
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
G
Igf1r
insulin-like growth factor 1 receptor
affects expression decreases expression
ISO EXP
tanespimycin affects the expression of IGF1R protein tanespimycin results in decreased expression of IGF1R protein
CTD
PMID:22810956
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
G
Ilf3
interleukin enhancer binding factor 3
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of ILF3 protein
CTD
PMID:31370342
NCBI chr 8:19,922,409...19,960,495
Ensembl chr 8:19,922,460...19,960,350
G
Kcnv2
potassium voltage-gated channel modifier subfamily V member 2
decreases expression multiple interactions
ISO
tanespimycin analog results in decreased expression of KCNV2 protein [tanespimycin co-treated with VER 155008] results in decreased expression of KCNV2 protein
CTD
PMID:31370342
NCBI chr 1:224,999,552...225,014,062
Ensembl chr 1:224,999,552...225,014,062
G
Kdm3a
lysine demethylase 3A
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of KDM3A protein
CTD
PMID:31370342
NCBI chr 4:103,630,907...103,675,073
Ensembl chr 4:103,630,908...103,675,073
G
Kdr
kinase insert domain receptor
affects expression decreases expression
ISO EXP
tanespimycin affects the expression of KDR protein tanespimycin results in decreased expression of KDR protein
CTD
PMID:22810956
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
G
Kit
KIT proto-oncogene receptor tyrosine kinase
decreases expression multiple interactions
ISO EXP
tanespimycin results in decreased expression of KIT protein tanespimycin results in increased degradation of and results in decreased expression of KIT protein
CTD
PMID:16061882 PMID:16213582 PMID:22810956
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
G
Larp7
La ribonucleoprotein 7, transcriptional regulator
increases expression
ISO
tanespimycin analog results in increased expression of LARP7 protein
CTD
PMID:31370342
NCBI chr 2:215,997,641...216,012,833
Ensembl chr 2:215,997,649...216,012,865
G
Lcp1
lymphocyte cytosolic protein 1
increases expression multiple interactions
ISO
tanespimycin analog results in increased expression of LCP1 protein [tanespimycin co-treated with VER 155008] results in increased expression of LCP1 protein
CTD
PMID:31370342
NCBI chr15:50,443,300...50,544,682
Ensembl chr15:50,488,149...50,544,680
G
Ldha
lactate dehydrogenase A
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of LDHA protein
CTD
PMID:31370342
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
G
Ldhb
lactate dehydrogenase B
increases expression
ISO
tanespimycin analog results in increased expression of LDHB protein
CTD
PMID:31370342
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
G
Lmna
lamin A/C
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of LMNA protein
CTD
PMID:31370342
NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
G
Lrpprc
leucine-rich pentatricopeptide repeat containing
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of LRPPRC protein
CTD
PMID:31370342
NCBI chr 6:9,859,816...9,942,294
Ensembl chr 6:9,859,867...9,942,293
G
Map2k6
mitogen-activated protein kinase kinase 6
multiple interactions
ISO
[salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP mRNA]; [salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP protein]
CTD
PMID:30796972
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
G
Mapk1
mitogen activated protein kinase 1
decreases phosphorylation affects expression multiple interactions
ISO EXP
tanespimycin results in decreased phosphorylation of MAPK1 protein tanespimycin affects the expression of MAPK1 protein tanespimycin affects the reaction [Cannabidiol affects the expression of MAPK1 protein] tanespimycin results in increased expression of and results in decreased phosphorylation of MAPK1 protein
CTD
PMID:17157164 PMID:20090934 PMID:21502504 PMID:22810956 PMID:24784839 PMID:26504004 More...
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
G
Mapk3
mitogen activated protein kinase 3
decreases phosphorylation affects expression multiple interactions
ISO EXP
tanespimycin results in decreased phosphorylation of MAPK3 protein tanespimycin affects the expression of MAPK3 protein tanespimycin affects the reaction [Cannabidiol affects the expression of MAPK3 protein] tanespimycin results in increased expression of and results in decreased phosphorylation of MAPK3 protein
CTD
PMID:17157164 PMID:20090934 PMID:21502504 PMID:22810956 PMID:24784839 PMID:26504004 More...
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
G
Mcl1
MCL1 apoptosis regulator, BCL2 family member
decreases expression
ISO
tanespimycin results in decreased expression of MCL1 protein
CTD
PMID:16923571
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
G
Mdm2
MDM2 proto-oncogene
increases degradation
ISO
tanespimycin results in increased degradation of MDM2 protein
CTD
PMID:17157164
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
G
Met
MET proto-oncogene, receptor tyrosine kinase
decreases expression
EXP ISO
tanespimycin results in decreased expression of MET protein
CTD
PMID:22810956
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
G
Mif
macrophage migration inhibitory factor
multiple interactions decreases expression
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of MIF protein tanespimycin results in decreased expression of MIF protein
CTD
PMID:31370342
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504 Ensembl chr 4:12,790,902...12,799,504
G
Mllt10
MLLT10, histone lysine methyltransferase DOT1L cofactor
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of MLLT10 protein
CTD
PMID:31370342
NCBI chr17:80,821,870...80,949,349
Ensembl chr17:80,822,556...80,949,345
G
Mmp2
matrix metallopeptidase 2
multiple interactions
ISO
tanespimycin affects the reaction [Nickel results in increased activity of MMP2 protein]; tanespimycin inhibits the reaction [Nickel results in increased expression of MMP2 mRNA]
CTD
PMID:21401309
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
G
Mmp9
matrix metallopeptidase 9
multiple interactions
ISO
tanespimycin affects the reaction [Nickel results in increased activity of MMP9 protein]; tanespimycin inhibits the reaction [Nickel results in increased expression of MMP9 mRNA]
CTD
PMID:21401309
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
G
Msn
moesin
increases expression
ISO
tanespimycin analog results in increased expression of MSN protein
CTD
PMID:31370342
NCBI chr X:60,996,043...61,064,011
Ensembl chr X:60,995,951...61,065,628
G
Mtap
methylthioadenosine phosphorylase
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of MTAP protein
CTD
PMID:31370342
NCBI chr 5:103,874,460...103,920,684
Ensembl chr 5:103,873,020...103,939,406
G
Mtss1
MTSS I-BAR domain containing 1
increases expression
ISO
tanespimycin results in increased expression of MTSS1 mRNA
CTD
PMID:19514085
NCBI chr 7:90,488,751...90,628,007
Ensembl chr 7:90,488,754...90,627,968
G
Nampt
nicotinamide phosphoribosyltransferase
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of NAMPT protein
CTD
PMID:31370342
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
G
Nans
N-acetylneuraminate synthase
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of NANS protein
CTD
PMID:31370342
NCBI chr 5:60,780,441...60,797,583
Ensembl chr 5:60,780,392...60,814,950
G
Ncl
nucleolin
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of NCL protein
CTD
PMID:31370342
NCBI chr 9:86,999,588...87,008,112
Ensembl chr 9:86,998,019...87,008,136
G
Nfkbia
NFKB inhibitor alpha
increases expression decreases phosphorylation
EXP ISO
tanespimycin results in increased expression of NFKBIA protein tanespimycin results in decreased phosphorylation of NFKBIA protein
CTD
PMID:11835313 PMID:22810956
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
G
Nos2
nitric oxide synthase 2
multiple interactions decreases expression
EXP
Quercetin inhibits the reaction [tanespimycin results in decreased expression of NOS2 mRNA]
CTD
PMID:11835313
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
G
Nqo1
NAD(P)H quinone dehydrogenase 1
multiple interactions increases response to substance increases reduction increases abundance
ISO
[5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione results in decreased activity of NQO1 protein] which results in decreased abundance of tanespimycin; [5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione results in decreased activity of NQO1 protein] which results in decreased abundance of tanespimycin metabolite; [5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione results in decreased activity of NQO1 protein] which results in decreased susceptibility to tanespimycin; [NQO1 protein results in increased reduction of tanespimycin] which results in increased chemical synthesis of tanespimycin metabolite; [tanespimycin co-treated with NQO1 protein] results in decreased expression of CDC25C protein; [tanespimycin co-treated with NQO1 protein] results in decreased expression of CDK1 protein NQO1 protein results in increased susceptibility to tanespimycin NQO1 protein results in increased abundance of tanespimycin; NQO1 protein results in increased abundance of tanespimycin metabolite
CTD
PMID:10564678 PMID:21156818 PMID:24552538
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:35,295,573...35,310,557
G
Oat
ornithine aminotransferase
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of OAT protein
CTD
PMID:31370342
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
G
Pa2g4
proliferation-associated 2G4
multiple interactions increases expression
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of PA2G4 protein tanespimycin analog results in increased expression of PA2G4 protein; tanespimycin results in increased expression of PA2G4 protein
CTD
PMID:31370342
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
G
Parp1
poly (ADP-ribose) polymerase 1
increases cleavage
EXP ISO
tanespimycin results in increased cleavage of PARP1 protein
CTD
PMID:22810956
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
G
Parp2
poly (ADP-ribose) polymerase 2
increases expression
ISO
tanespimycin analog results in increased expression of PARP2 protein
CTD
PMID:31370342
NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338
G
Pdgfrb
platelet derived growth factor receptor beta
decreases expression
ISO EXP
tanespimycin results in decreased expression of PDGFRB protein
CTD
PMID:22810956
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
G
Pdia4
protein disulfide isomerase family A, member 4
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of PDIA4 protein
CTD
PMID:31370342
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
G
Pfn1
profilin 1
increases expression
ISO
tanespimycin analog results in increased expression of PFN1 protein
CTD
PMID:31370342
NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631
G
Pgr
progesterone receptor
decreases expression
ISO
tanespimycin results in decreased expression of PGR protein
CTD
PMID:11448926
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
G
Pip4k2c
phosphatidylinositol-5-phosphate 4-kinase type 2 gamma
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of PIP4K2C protein
CTD
PMID:31370342
NCBI chr 7:63,020,004...63,035,086
Ensembl chr 7:63,020,000...63,035,078
G
Pkm
pyruvate kinase M1/2
decreases expression
ISO
tanespimycin results in decreased expression of PKM protein
CTD
PMID:31370342
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
G
Pnn
pinin, desmosome associated protein
increases expression
ISO
tanespimycin results in increased expression of PNN mRNA
CTD
PMID:19514085
NCBI chr 6:76,758,138...76,766,451
Ensembl chr 6:76,758,117...76,766,889
G
Prkrip1
PRKR interacting protein 1
increases expression
ISO
tanespimycin analog results in increased expression of PRKRIP1 protein
CTD
PMID:31370342
NCBI chr12:20,470,802...20,491,789
Ensembl chr12:20,470,820...20,489,115
G
Prps2
phosphoribosyl pyrophosphate synthetase 2
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of PRPS2 protein
CTD
PMID:31370342
NCBI chr X:26,975,915...27,013,184
Ensembl chr X:26,976,061...27,013,181
G
Psma6
proteasome 20S subunit alpha 6
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of PSMA6 protein
CTD
PMID:31370342
NCBI chr 6:72,765,534...72,796,554
Ensembl chr 6:72,765,473...72,796,554
G
Psma7
proteasome 20S subunit alpha 7
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of PSMA7 protein
CTD
PMID:31370342
NCBI chr 3:167,137,279...167,143,626
Ensembl chr 3:167,137,263...167,143,672
G
Rab17
RAB17, member RAS oncogene family
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of RAB17 protein
CTD
PMID:31370342
NCBI chr 9:91,552,924...91,566,759
Ensembl chr 9:91,553,464...91,566,451
G
Raf1
Raf-1 proto-oncogene, serine/threonine kinase
decreases expression
ISO
tanespimycin results in decreased expression of RAF1 protein
CTD
PMID:10564678 PMID:34291863
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
G
Rb1
RB transcriptional corepressor 1
decreases phosphorylation multiple interactions
ISO
tanespimycin results in decreased phosphorylation of RB1 protein [tanespimycin co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein
CTD
PMID:17121904
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
G
Rdx
radixin
increases expression multiple interactions
ISO
tanespimycin analog results in increased expression of RDX protein [tanespimycin co-treated with VER 155008] results in increased expression of RDX protein
CTD
PMID:31370342
NCBI chr 8:52,379,494...52,437,673
Ensembl chr 8:52,379,494...52,437,678
G
Rplp0
ribosomal protein lateral stalk subunit P0
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of RPLP0 protein
CTD
PMID:31370342
NCBI chr12:41,054,363...41,057,632
Ensembl chr12:41,054,179...41,057,632
G
Rps6
ribosomal protein S6
decreases phosphorylation decreases expression
ISO
tanespimycin results in decreased phosphorylation of RPS6 protein tanespimycin results in decreased expression of RPS6 protein
CTD
PMID:17121904 PMID:27255535
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
G
Runx1
RUNX family transcription factor 1
decreases expression
ISO
tanespimycin results in decreased expression of RUNX1 protein mutant form
CTD
PMID:33609515
NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542
G
Runx1t1
RUNX1 partner transcriptional co-repressor 1
decreases expression
ISO
tanespimycin results in decreased expression of RUNX1T1 protein mutant form
CTD
PMID:33609515
NCBI chr 5:27,187,674...27,338,070
Ensembl chr 5:27,187,551...27,335,592
G
Selenbp1
selenium binding protein 1
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of SELENBP1 protein
CTD
PMID:31370342
NCBI chr 2:182,494,004...182,504,594
Ensembl chr 2:182,493,978...182,504,594
G
Serpinb5
serpin family B member 5
increases expression
ISO
tanespimycin results in increased expression of SERPINB5 mRNA
CTD
PMID:19514085
NCBI chr13:22,985,557...23,005,756
Ensembl chr13:22,985,557...23,005,756
G
Shmt2
serine hydroxymethyltransferase 2
decreases expression
ISO
tanespimycin analog results in decreased expression of SHMT2 protein
CTD
PMID:31370342
NCBI chr 7:63,358,961...63,364,293
Ensembl chr 7:63,358,961...63,364,236
G
Sod2
superoxide dismutase 2
increases abundance increases response to substance
ISO
SOD2 protein results in increased abundance of tanespimycin metabolite SOD2 protein results in increased susceptibility to tanespimycin
CTD
PMID:21156818
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
G
Srcin1
SRC kinase signaling inhibitor 1
increases expression multiple interactions
ISO
tanespimycin analog results in increased expression of SRCIN1 protein; tanespimycin results in increased expression of SRCIN1 protein [tanespimycin co-treated with VER 155008] results in increased expression of SRCIN1 protein
CTD
PMID:31370342
NCBI chr10:82,502,911...82,569,882
Ensembl chr10:82,504,393...82,571,040
G
Tagln2
transgelin 2
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of TAGLN2 protein
CTD
PMID:31370342
NCBI chr13:84,966,980...84,973,973
Ensembl chr13:84,967,009...84,973,972
G
Timp3
TIMP metallopeptidase inhibitor 3
increases expression
ISO
tanespimycin results in increased expression of TIMP3 mRNA
CTD
PMID:19514085
NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
G
Tnfsf10
TNF superfamily member 10
multiple interactions
ISO
[tanespimycin co-treated with TNFSF10 protein] results in decreased expression of XIAP protein; [tanespimycin co-treated with TNFSF10 protein] results in increased activity of CASP3 protein
CTD
PMID:15993848
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
G
Tp53
tumor protein p53
decreases expression
ISO
tanespimycin results in decreased expression of TP53 protein
CTD
PMID:10564678
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Tpte2
transmembrane phosphoinositide 3-phosphatase and tensin homolog 2
increases expression
ISO
tanespimycin analog results in increased expression of TPTE2 protein
CTD
PMID:31370342
NCBI chr16:69,658,874...69,756,571
Ensembl chr16:69,658,875...69,752,949
G
Tymp
thymidine phosphorylase
decreases expression multiple interactions
ISO
tanespimycin results in decreased expression of TYMP mRNA; tanespimycin results in decreased expression of TYMP protein [salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP mRNA]; [salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP protein]; [tanespimycin co-treated with salinomycin] results in decreased expression of TYMP mRNA; acetylleucyl-leucyl-norleucinal inhibits the reaction [tanespimycin inhibits the reaction [salinomycin results in increased expression of TYMP protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [tanespimycin inhibits the reaction [salinomycin results in increased expression of TYMP protein]]; SB 203580 promotes the reaction [[tanespimycin co-treated with salinomycin] results in decreased expression of TYMP mRNA]; tanespimycin inhibits the reaction [Dactinomycin promotes the reaction [salinomycin results in increased expression of TYMP mRNA]]; tanespimycin inhibits the reaction [salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]]; tanespimycin inhibits the reaction [salinomycin results in increased expression of TYMP mRNA]; tanespimycin inhibits the reaction [salinomycin results in increased expression of TYMP protein]
CTD
PMID:30796972
NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
G
Tyms
thymidylate synthetase
decreases expression
ISO
tanespimycin results in decreased expression of TYMS protein
CTD
PMID:18830594
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
G
Ugdh
UDP-glucose 6-dehydrogenase
increases expression
ISO
tanespimycin analog results in increased expression of UGDH protein; tanespimycin results in increased expression of UGDH protein
CTD
PMID:31370342
NCBI chr14:42,848,704...42,872,351
Ensembl chr14:42,848,854...42,872,354
G
Ugp2
UDP-glucose pyrophosphorylase 2
decreases expression
ISO
tanespimycin results in decreased expression of UGP2 protein
CTD
PMID:31370342
NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830
G
Vil1
villin 1
increases expression
ISO
tanespimycin analog results in increased expression of VIL1 protein
CTD
PMID:31370342
NCBI chr 9:75,991,141...76,018,860
Ensembl chr 9:75,991,141...76,018,858
G
Xiap
X-linked inhibitor of apoptosis
multiple interactions
ISO
[tanespimycin co-treated with TNFSF10 protein] results in decreased expression of XIAP protein
CTD
PMID:15993848
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
G
Yars1
tyrosyl-tRNA synthetase 1
multiple interactions
ISO
[tanespimycin co-treated with VER 155008] results in decreased expression of YARS1 protein
CTD
PMID:31370342
NCBI chr 5:141,535,815...141,564,029
Ensembl chr 5:141,535,759...141,563,833
G
Zyg11b
zyg-11 family member B, cell cycle regulator
multiple interactions increases expression
ISO
[tanespimycin co-treated with VER 155008] results in increased expression of ZYG11B protein tanespimycin analog results in increased expression of ZYG11B protein
CTD
PMID:31370342
NCBI chr 5:122,985,548...123,042,735
Ensembl chr 5:122,992,147...123,042,736
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all